For example, in melanoma, there are currently three FDA-approved combinations of inhibitors of BRAFV600E plus MEK1/2: dabrafenib plus trametinib (Novartis), vemurafenib plus cobimetinib (Genentech/Plexxicon/Roche), and encorafenib plus binimetinib (Pfizer), based on high response rates of 50–80% (Figure 1) [18,19,20,21,22]. Here, MAP2K1 is linked to melanoma.